Diagnosis of an additional in situ melanoma does not influence survival for patients with a single invasive melanoma: A registry-based follow-up study

Australasian Journal of Dermatology

Volumn 57, Issue 1, 2016, Pages 57-60

  Youlden, Danny R ^a   Khosrotehrani, Kiarash ^b   Green, Adèle C ^c,d   Soyer, H Peter ^b   Kimlin, Michael G ^e   Youl, Philippa H ^a   Aitken, Joanne F ^a   Baade, Peter D ^a  

^a CANCER COUNCIL QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF THE SUNSHINE COAST   (Australia)

Author keywords

in situ; invasive; melanoma; survival

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; AUSTRALIA; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; TUMOR LOCALIZATION; TUMOR VOLUME; VERY ELDERLY; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; QUEENSLAND; REGISTER; SECOND CANCER; SKIN TUMOR; SURVIVAL RATE; TUMOR INVASION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, SECOND PRIMARY; QUEENSLAND; REGISTRIES; SKIN NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84958105631     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/ajd.12429     Document Type: Article

References (10)

1. Mocellin S, Nitti D,. Cutaneous melanoma in situ: translational evidence from a large population-based study. Oncologist 2011; 16: 896-903.
2. Youlden DR, Youl PH, Soyer HP, et al,. Distribution of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma Queensland, Australia, 1982-2010. JAMA Dermatol. 2014; 150: 526-34.
3. Higgins HW 2nd, Lee KC, Galan A, et al,. Melanoma in situ: Part I. Epidemiology, screening, and clinical features. J. Am. Acad. Dermatol. 2015; 73: 181-90.
4. Sturm RA, Fox C, McClenahan P, et al,. Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients. J. Invest. Dermatol. 2014; 134: 141-9.
5. Darrasse-Jeze G, Bergot AS, Durgeau A, et al,. Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J. Clin. Invest. 2009; 119: 2648-62.
6. Royston P, Lambert PC,. Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model. College Station, TX: Stata Press, 2011.
7. Doubrovsky A, Menzies SW,. Enhanced survival in patients with multiple primary melanoma. Arch. Dermatol. 2003; 139: 1013-8.
8. Kricker A, Armstrong BK, Goumas C, et al,. Survival for patients with single and multiple primary melanomas: the genes, environment, and melanoma study. JAMA Dermatol. 2013; 149: 921-7.
9. Rowe CJ, Law MH, Palmer JM, et al,. Survival outcomes in patients with multiple primary melanomas. J. Eur. Acad. Dermatol. Venereol. 2015; 29: 2120-7.
10. Lachiewicz AM, Berwick M, Wiggins CL, et al,. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch. Dermatol. 2008; 144: 515-21.